Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Clinical studies with imatinib in 2004].

Sándor Eckhardt1

  • 1Országos Onkolágiai Intézet, Budapest. eckhardt@oncol.hu

Orvosi Hetilap
|June 1, 2005
PubMed
Summary
This summary is machine-generated.

Imatinib is a targeted therapy drug effective against chronic myeloid leukemia and other cancers. It offers a new perspective for successful molecular therapy with a tolerable toxicity profile.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Systemic therapy of breast cancer: practice guideline].

Magyar onkologia·2016
Same author

Inflammatory breast cancer-comparing the effectivity of preoperative docetaxel-epirubicine protocol to conventional antracycline-containing chemotherapy to achieve clinical benefit and complete pathological response.

Pathology oncology research : POR·2010
Same author

[Pharmaceutical therapy of breast cancer].

Magyar onkologia·2010
Same author

Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry.

The Journal of molecular diagnostics : JMD·2008
Same author

Molecular targeted therapy: a strategy of disillusions or optimism?

The Journal of laboratory and clinical medicine·2006
Same author

[Effect of imatinib treatment of gastrointestinal stromal tumors].

Orvosi hetilap·2003
Same journal

[The application of artificial intelligence in healthcare: benefits, challenges, and issues of responsibility].

Orvosi hetilap·2026
Same journal

[Long-COVID syndrome and lung-specific abnormalities following COVID-19].

Orvosi hetilap·2026
Same journal

[Validation of the Vaccination Attitudes Examination (VAX) scale in Hungary].

Orvosi hetilap·2026
Same journal

Orvosi hetilap·2026
Same journal

[The Hungarian short version and psychometric properties of the Activities-specific Balance Confidence Scale for assessing fall risk].

Orvosi hetilap·2026
Same journal

[Hungarian primary care: facts, problems and expectations].

Orvosi hetilap·2026
See all related articles

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Context:

  • Targeted molecular therapies have revolutionized cancer treatment.
  • Imatinib represents a significant advancement in this field.
  • The drug's mechanism involves inhibiting specific tyrosine kinases.

Purpose:

  • To review the therapeutic applications and potential of imatinib.
  • To discuss its efficacy in various malignancies.
  • To explore ongoing research and future directions.

Summary:

  • Imatinib targets the abl-bcr protein, crucial in chronic myeloid leukemia (CML).
  • It also acts on C-kit, PDGFRalpha/beta, and other mutations, treating gastrointestinal stromal tumors (GIST), dermatofibrosarcoma protuberans, and hypereosinophilic syndrome.

Related Experiment Videos

  • Ongoing studies investigate imatinib's role in other solid tumors and strategies to overcome resistance.

    • Impact:

    • Imatinib offers a new, orally administered, and well-tolerated targeted therapy option.
    • It signifies a paradigm shift towards personalized molecular medicine in oncology.
    • Further research promises to expand its clinical utility and address treatment resistance.